Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
Allakos is a clinical-stage company developing therapeutic antibodies that selecti...
Allakos is a clinical-stage company developing ...
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of h...
Bio-Techne Corporation (NASDAQ: TECH) is a lead...
Akari is a biopharmaceutical company focused on developing inhibitors of acute and...
Akari is a biopharmaceutical company focused on...
The objective of Phenomix Sciences, LLC (Phenomix) is to provide healthcare soluti...
The objective of Phenomix Sciences, LLC (Phenom...
Join the National Investor Network and get the latest information with your interests in mind.